prednisone

P3, N=34, Completed, University Hospital, Brest | Active, not recruiting --> Completed

P2/3, N=960, Not yet recruiting, Merck Sharp & Dohme LLC

Second, a network meta-analysis ranked the efficacy and safety of regimens including rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (DA-EPOCH-R); R-CHOP plus lenalidomide (R2-CHOP); R-CHOP plus ibrutinib (I+R-CHOP); R-CHOP plus zanubrutinib (Z+R-CHOP); and R-CHOP plus venetoclax (Ven-R-CHOP). DEL is a distinct high-risk subtype with quantifiable prognostic detriment. Z+R-CHOP emerges as a promising strategy requiring validation in prospective studies.

P1/2, N=67, Completed, Fondazione Gimema Franco Mandelli Onlus | Active, not recruiting --> Completed

P4, N=104, Not yet recruiting, Columbia University

P2, N=223, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial completion date: Apr 2026 --> Apr 2028

Upon confirming KHE diagnosis, we initiated a combined sirolimus and prednisone treatment. In this report, we also discuss the clinical manifestations, imaging features, histopathological characteristics, and treatment options for this KHE subtype and review relevant literature. This case highlights the diagnostic features and therapeutic considerations of superficial KHE without KMP, emphasizing the importance of multidisciplinary evaluation.

Through integrative multiomics profiling, we identified tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) as a key prognostic determinant associated with predicted R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) resistance, specifically localizing its expression to tumor-associated macrophages (TAMs). Additionally, a novel risk model derived from the TNFRSF1A+ TAM transcriptional signature demonstrated robust predictive accuracy for patient outcomes across independent cohorts. Our findings elucidate the role of TNFRSF1A+ TAMs in driving DLBCL progression, highlight the TNFRSF1A/NF-κB/BAFF axis as a vulnerability in the DLBCL microenvironment, and propose curcumin as a viable therapeutic strategy to disrupt this supportive microenvironment.

P2/3, N=207, Active, not recruiting, Sobi Inc. | Recruiting --> Active, not recruiting

P1/2, N=148, Active, not recruiting, Assistance Publique Hopitaux De Paris | Recruiting --> Active, not recruiting

P1/2, N=148, Recruiting, DualityBio Inc. | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Mar 2026 --> Jun 2027

P3, N=5000, Not yet recruiting, Exelixis